A novel circular RNA circPPFIA1 promotes laryngeal squamous cell carcinoma progression through sponging miR-340-3p and regulating ELK1 expression.
Circppfia1
ceRNA
elk1
lscc
miR-340-3p
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
entrez:
30
8
2021
pubmed:
31
8
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Abnormal expression of circular RNA (circRNA) is closely related to the occurrence and development of many cancers. By screening the expression of circRNA, we identified a novel circRNA termed as has_circ_0023326 in laryngeal squamous cell carcinoma (LSCC). We verified the expression of circPPFIA1 and found that it was upregulated in LSCC tissues compared to the adjacent normal tissues. Functional studies were carried out to detect the effect of circPPFIA1 expression on the phenotype of LSCC cells. These results suggest that circPPFIA1 knockdown can suppress the proliferation, migration, and invasion of LSCC cells, while circPPFIA1 overexpression can promote these processes. Mechanistically, miR-340-3p was predicted to be the target miRNA sponged by circPPFIA1 as confirmed through the luciferase assay and rescue experiments. In addition, miR-340-3p was found to target ELK1 and inhibit its expression. Taken together, circPPFIA1 promotes the progression of LSCC via the miR-340-3p/ELK1 signaling axis, which may serve as a novel prognostic or therapeutic target for LSCC.
Identifiants
pubmed: 34455918
doi: 10.1080/21655979.2021.1959866
pmc: PMC8806628
doi:
Substances chimiques
ELK1 protein, human
0
MIRN340 microRNA, human
0
MicroRNAs
0
RNA, Circular
0
ets-Domain Protein Elk-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5220-5230Références
Bioengineered. 2020 Dec;11(1):311-317
pubmed: 32107956
J Hematol Oncol. 2017 Jan 25;10(1):32
pubmed: 28122647
Eur J Cancer. 2017 Feb;72:112-123
pubmed: 28027514
Comput Struct Biotechnol J. 2021 Jan 22;19:910-928
pubmed: 33598105
J Cell Biochem. 2019 Oct;120(10):16921-16933
pubmed: 31104318
CA Cancer J Clin. 2017 Jan;67(1):31-50
pubmed: 27898173
J Biol Chem. 2020 Nov 20;295(47):16058-16071
pubmed: 32938713
Eur Arch Otorhinolaryngol. 2011 Feb;268(2):165-79
pubmed: 20957488
Pharmacol Ther. 2018 Jul;187:31-44
pubmed: 29406246
Oncogenesis. 2020 Mar 6;9(3):32
pubmed: 32144235
Onco Targets Ther. 2020 Jun 12;13:5529-5539
pubmed: 32606768
Mol Cancer. 2020 Mar 12;19(1):57
pubmed: 32164715
Trends Cancer. 2020 Apr;6(4):319-336
pubmed: 32209446
Bioengineered. 2021 Dec;12(1):3014-3028
pubmed: 34180753
Oncol Rep. 2018 Sep;40(3):1769-1776
pubmed: 30015900
Otolaryngol Clin North Am. 2008 Aug;41(4):673-95, v
pubmed: 18570953
Life Sci. 2018 Nov 15;213:9-17
pubmed: 30308183
Mol Cancer. 2007 Sep 25;6:60
pubmed: 17894887
Front Oncol. 2020 Jun 24;10:906
pubmed: 32670874
Clin Cardiol. 2016 Jan;39(1):19-23
pubmed: 26748815
Front Oncol. 2020 Feb 04;10:60
pubmed: 32117723
Mol Cancer. 2020 Dec 14;19(1):172
pubmed: 33317550
Mol Cancer. 2019 Jan 9;18(1):6
pubmed: 30626395
Oncol Rep. 2017 Oct;38(4):2155-2165
pubmed: 28791411
Mol Cancer. 2018 Nov 20;17(1):162
pubmed: 30458787
Bioengineered. 2020 Dec;11(1):932-938
pubmed: 32867570
Gene. 2016 Feb 15;577(2):193-201
pubmed: 26656176
Proteomics. 2019 Nov;19(21-22):e1900020
pubmed: 31169343
Oncol Lett. 2020 Oct;20(4):80
pubmed: 32863913
Oncotarget. 2016 Dec 27;7(52):85948-85962
pubmed: 27852061
Nat Cell Biol. 2020 Sep;22(9):1056-1063
pubmed: 32807901
Mol Cancer. 2020 Jan 23;19(1):14
pubmed: 31973726
J Exp Clin Cancer Res. 2016 Jan 29;35:22
pubmed: 26822763